Evidence map›Paper›PMID 41694991›Full record

ArticleCureus2026

Solitary Fibrous Tumor With a 12-Year Recurrence Interval in a Female Patient: A Case Report.

Diana Laura Rodríguez Carrillo, Begoña Llaca Morfin, Moises Brener Chaoul, Carlos D Robles Vidal

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Diana Laura Rodríguez CarrilloGeneral Surgery, Hospital Angeles Lomas, Huixquilucan, MEX.
Begoña Llaca MorfinGeneral Surgery, Hospital Angeles Lomas, Huixquilucan, MEX.
Moises Brener ChaoulSurgical Oncology, Hospital Angeles Lomas, Huixquilucan, MEX.
Carlos D Robles VidalSurgical Oncology, Hospital Angeles Lomas, Huixquilucan, MEX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm characterized by unpredictable biological behavior, with the potential for late recurrence even in tumors initially classified as low risk. We report the case of an 83-year-old woman with a history of complete resection of a right thoracic SFT 12 years earlier, who was found on surveillance imaging to have a new anterior left mediastinal mass. Positron emission tomography-computed tomography (PET-CT) demonstrated low metabolic activity (maximum standardized uptake value (SUVmax) 2.32). Surgical exploration revealed a 6.5 × 5 cm lesion adherent to the pericardial pleura, which was completely resected. Histopathologic examination showed a spindle cell neoplasm with a patternless architecture, without hypercellularity, necrosis, or pleomorphism. Immunohistochemistry demonstrated strong nuclear positivity for signal transducer and activator of transcription 6 (STAT6) and diffuse CD34 expression, with negative S100 protein and muscle markers. Risk stratification using the Demicco model categorized the tumor as low risk. Review of the original tumor resected in 2013, which measured 19.3 × 16.2 cm, revealed similar histologic features and an intermediate-risk score. The long disease-free interval raises the diagnostic dilemma of late recurrence versus a metachronous SFT, a distinction that remains challenging due to shared morphologic and molecular characteristics. This case underscores the limitations of metabolic imaging in indolent SFTs and highlights the importance of complete surgical resection and long-term, potentially lifelong, surveillance.

Indexed as

follow-upmediastinummetachronous tumorrecurrencesolitary fibrous tumor

Identifiers

PMID41694991
PMCPMC12906129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.